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The efficacy of adenovirus-mediated gene therapy for
treatment of metastatic B16 melanomas, established in
syngeneic C57BL/6 mice, was assessed via an ex vivo
cytokine vaccine approach or via an in vivo strategy
utilizing combination cytokine/herpes simplex virus-
thymidine kinase (HSV-tk) suicide gene delivery and
treatment with ganciclovir (GCV). In the ex vivo tumor
vaccine approach, B16 melanoma cells, transduced in vitro
by adenovirus containing either interleukin (IL)-2, gran-
ulocyte-macrophage colony stimulating factor (GM-
CSF), or tumor necrosis factor-a cytokine genes and g
irradiated, were subcutaneously injected into the flank
and a distant subcutaneous challenge injection of
unmodified B16 melanoma cells was performed 15 d
later. Significant reductions in challenge tumor volume
were observed in the IL-2 group (75% reduction; p J0.02)
and in the GM-CSF group (88% reduction; p J0.0006),
whereas the effect for tumor necrosis factor-a was not
The increasing incidence of melanoma, possibly due tothe increased exposure to ultraviolet (UV)-B irradiation(Marks, 1995; Donawho and Kripke, 1995), coupled tothe highly metastatic nature and unsuccessful surgical,chemotherapeutic, and radiologic treatment modalities
(Johnson et al, 1995), makes the development of novel therapies a high
priority. Recent advances in the treatment of malignancy by somatic
gene therapy techniques may offer the greatest chance of success (NIH
Recombinant DNA Advisory Committee, 1996). To date, rapid
development of new gene delivery systems (Mulligan, 1993; Pardoll,
1995; Nabel et al, 1996) provides a platform strategy that has attempted
to treat metastatic melanoma via enhancing the host’s immune responses.
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statistically significant. In the in vivo treatment of estab-
lished melanomas, this cytokine approach was combined
with a suicide gene therapy and subcutaneous B16 melan-
omas were directly injected with (i) IL-2/recombinant,
replication-deficient adenovirus (adv) and thymidine kin-
ase (tk)/adv, (ii) GM-CSF/adv, IL-2/adv, and tk/adv, or
(iii) control b-galactosidase (b-gal)/adv and tk/adv. After
intraperitoneal application of GCV (10 mg per kg) for
6 d, the residual tumor masses were excised and the
animals challenged with unmodified B16 cells. Challenge
tumor growth was reduced by 56% for the IL-2/tk/adv/
GCV treatment (p 5 0.041) and by 77% for the GM-
CSF/IL-2/tk/adv/GCV treatment p (p J0.037), in com-
parison with the b-gal/tk/GCV control group. These
data may hold significant promise for the development
of effective ex vivo and in vivo gene therapy modalities to
counter the highly metastatic nature of human melan-
oma. Key words: cancer/cytokine/GM-CSF/HSV-thymidine
kinase/IL-2/TNF-a. J Invest Dermatol 110:867–871, 1998
Among the various paradigms to achieve an effective anti-metastatic
treatment, two promising cancer gene therapy approaches are repres-
ented by the ex vivo ‘‘cancer vaccine’’ approach and the so-called
‘‘combination’’ gene therapy, which involves in vivo delivery of an
immunologic gene and a cytotoxic gene. The cancer vaccine approach
employs preparations of irradiated, autologous, or allogeneic tumor
cells with or without admixed accessory cells, which have been
transduced with several cytokines or histocompatability genes in vitro.
Once returned to the host, an active immune response is induced,
which is assumed to be tumor cell specific, systemic, and provides for
long-term surveillance (Tahara and Lotze, 1995; Pardoll, 1995; Hwu
and Rosenberg, 1995; Armstrong et al, 1996). Alternatively, direct
gene delivery into tumors in vivo would be more desirable in a clinical
setting (Nabel and Nabel, 1995), and, moreover, transfer of an
immunologic gene can be coupled to ‘‘suicide’’ gene delivery where
a prodrug is converted into an agent cytotoxic to dividing cells,
resulting ideally in the destruction of the primary tumor while
concurrently providing for systemic anti-tumor immune surveillance
(Mulligan, 1993; Chen et al, 1995). In one suicide approach, transfer
of the gene encoding HSV thymidine kinase and treatment with
ganciclovir (GCV) is enhanced by the bystander effect, whereby
transduced cells confer GCV cytotoxicity to neighboring, nontrans-
duced, dividing cells (Moolten, 1986). This in part mimics the irradiated
cell immunogenicity component of the ex vivo vaccine approach,
augmenting further the strategic goals of the combination gene therapy.
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In terms of gene delivery, several systems have been assessed in
melanoma models including retroviral and nonviral vectors (Mulligan,
1993; Hart and Vile, 1994; Nabel et al, 1996). Alternatively, recombin-
ant, replication defective adenoviruses (adv) can be employed that have
significant advantages in terms of a physico-chemical stability, which
allows concentration to high virus titers (Wilson, 1996). In addition,
this viral vector does not integrate into the host genome, thus avoiding
insertional mutagenesis. Indeed, we have previously shown that aden-
oviral-mediated in vivo suicide gene therapy was effective for the
treatment of established B16 mouse and A375-SM human melanomas
(Bonnekoh et al, 1995, 1996). Thus, the aim of this study was to
evaluate adenoviral-mediated immuno-gene therapy and combination-
gene therapy approaches, to treat melanoma metastasis via ex vivo and
in vivo gene transfer strategies in the experimental B16 melanoma/
C57BL/6 mouse model (Fidler, 1975; Dranoff et al, 1993). In the ex
vivo vaccine approach, B16 melanoma cells transduced in vitro with
adv carrying interleukin (IL)-2 or granulocyte-macrophage colony
stimulating factor (GM-CSF), but not tumor necrosis factor (TNF)-α,
conferred protection against a distant site challenge with unmodified
B16 melanoma cells. Similarly, cytokine-dependent protection was
observed in vivo in combination with herpes simplex virus-thymidine
kinase (HSV-tk) gene transfer and GCV treatment. Given the increased
sensitivity to adenoviral transduction observed previously in human
versus mouse melanoma cells (Bonnekoh et al, 1996), these data possibly
under-represent the efficacy that may be achievable in the treatment
of human disease.
MATERIALS AND METHODS
Construction of recombinant, replication-defective adenoviruses The
construction of E1A-deficient adv serotype 5 containing the HSV-tk, the
murine IL-2, or the murine GM-CSF genes has been described previously
(Chen et al, 1995), and the TNF-α/adv was similarly constructed by
inserting the murine cDNA clone (ATCC cat. no. 53007, pAW731) into
an expression cassette consisting of the Rous sarcoma virus-long-terminal
repeat promoter and the polyadenylation site of the bovine growth hormone
gene situated in the deleted E1-region of the adenovirus virus backbone.
Control adenovirus carrying the β-galactosidase (β-gal) reporter gene
(Stratford-Perricaudet et al, 1992) or a replication-deficient DL312/adv vector
gene were kindly provided by Dr. M. Perricaudet (Institut Gustave Roussy,
Villejuif Cedex, France) and Dr. T. Shenk (Princeton University, NJ),
respectively. Advs were propagated in 293 cells, purified by caesium chloride
ultracentrifugation, with subsequent dialysis against 10 mM Tris-HCl, 1 mM
MgCl2, 10% glycerol, pH 7.4, and viral titers [plaque forming units (pfu)]
were determined by plaque assay on 293 cells, as described previously (Chen
et al, 1995).
Cell culture and in vitro adenoviral transduction Murine B16-F1 melan-
oma cells (Fidler, 1975) were routinely cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% (vol/vol) fetal bovine serum (Gibco-BRL,
Grand Island, NY). In order to avoid contamination of cells by xeno-antigens
from bovine serum, prior to injection, B16 cells were grown under serum-
free conditions in Ultraculture medium (Biowhittaker, Walkersville, MD)
supplemented with L-glutamine, for 3 d. To determine B16 cytokine secretion
following adenoviral transduction, 2 3 105 cells per 3.5 cm dish were transduced
24 h after plating with IL-2/adv or GM-CSF/adv, at varying multiplicities of
infection (MOI), in 1.5 ml of serum-free Dulbecco’s modified Eagle’s medium
for 3 h. The cells were then returned to Dulbecco’s modified Eagle’s medium/
10% serum and cultured for a further 2 d when conditioned medium was
harvested. Supernatant IL-2 content was determined by an enzyme-linked
immunosorbent assay (ELISA) (Intertest mouse IL-2 ELISA kit, Genzyme,
Cambridge, MA) and a T cell proliferation bioassay (Coligan et al, 1991), and
the GM-CSF concentration by ELISA (Endogen, Boston, MA). IL-2 and GM-
CSF secretion rates were calculated as U per 106 cells per 24 h. Additionally,
to determine the effect of irradiation on cytokine secretion, GM-CSF secretion
was measured following exposure to γ-irradiation. Here, 1.5 3 106 B16 cells
per 3.5 cm dish, infected with GM-CSF/adv at a MOI of 150 pfu per cell,
were γ-irradiated with 80 Gy (caesium-137) 24 h later and, over the following
3 d, the amount of GM-CSF accumulated was determined by ELISA.
Ex vivo treatment protocol Eight week old female C57BL/6 mice (Charles
River Laboratories, Wilmington, MA) received two consecutive tumor cell
‘‘vaccinations’’ at days 1 and 8 of B16 cells transduced the previous day with
adv at a MOI of 100 pfu per cell in serum-free Ultraculture medium. On days
1 and 8, transduced cells were trypsinised, washed in phosphate buffered saline
(PBS) and γ-irradiated with 80 Gy. Following irradiation, 4 3 106 adv-
transduced B16 cells were injected subcutaneously (s.c.) in 100 µl PBS into the
right flank (first vaccination) and into the left flank (second vaccination).
Control groups included treatment with (a) PBS only or (b) γ-irradiated,
uninfected B16 cells. At day 15, 2 3 105 viable (trypan blue exclusion) untreated
B16 challenge tumor cells, grown for 3 d in serum-free Ultraculture medium,
in 100 µl PBS, were injected s.c. in the mid-back. After 17–18 d, challenge tumor
volume was evaluated by three-dimensional micrometer-calliper measurement.
Assessment of long-term adenovirus persistence in established
melanomas Melanomas generated on the back of C57BL/6 mice by s.c.
injection of 5 3 105 B16 cells, were injected 10 d later with 1 3 109 pfu of
β-gal/adv in a total volume of 75 µl virus dialysis buffer. Intra-tumoral adv
injection was performed slowly (1 µl per 15 s) with a 30-gauge hypodermic
needle to minimize leakage. At 3, 9, and 15 d after the β-gal/adv treatment
the animals were sacrificed and, following volume measurement, each tumor
was powdered under liquid nitrogen, resuspended in 0.25 M Tris-HCl, pH 7.8,
with three subsequent thaw–freeze cycles, and β-gal enzyme activity measured
by a chemiluminescent assay (Galacto-Light, Tropix, Bedford, MA). β-gal
activities (mU) were calculated for each tumor with respect to the total volume
of the lysate prepared from a given tumor, and background β-gal activity from
untreated tumor tissue (54 6 31 µU per mm3, n 5 5) was subtracted.
In vivo combination treatment protocol: transfer of cytokine and
HSV-tk genes into established melanomas and challenge with B16
cells Melanomas established in female 8 wk old C57BL/6 mice by s.c.
injection of 3–5 3 105 B16 cells on the lower mid-back were injected at 10–
14 d with tk/adv and IL-2/adv or GM-CSF/adv and/or β-gal/adv. Initially,
to test the suicide approach in immunocompetent mice, melanomas were
injected with 1 3 109 pfu of HSV tk-adv or virus-dialysis buffer as a control.
The next day tk/adv- and buffer-injected animals were randomized with respect
to initial tumor size and divided into GCV-treated (Cytovene, Syntex, Palo
Alto, CA) or intraperitoneal (i.p.) mock, isotonic sodium chloride-treated
groups. To determine a minimum efficacy of GCV treatment, two experiments
were performed, employing 75 or 10 mg GCV per kg body weight. GCV was
injected i.p. twice daily for 6 d and tumor volume was measured at day 7
(Bonnekoh et al, 1995). In combination gene therapy experiments, this basic
protocol was modified to include injection of tk-adv with 2 3 108 pfu of IL-
2/adv and/or 3 3 107 pfu of GM-CSF/adv employing gal/adv injection as a
control. A GCV dosage of 10 mg per kg body weight treatment regime was
applied twice daily for 6 d. At 7–10 d after adv injection, residual tumor tissue
was carefully excised, and 2–4 d later the animals were challenged with a s.c.
injection of 5 3 104–1.5 3 105 untreated B16 cells, and 2 wk later challenge
melanoma growth was measured by microcalipers.
Cytotoxic T-lymphocyte assay In order to evaluate the mechanism of the
immune response, an in vitro CTL assay was performed 3 d after conclusion of
GCV treatment in the HSV-tk/IL-2 treated group as described previously
(Chen et al, 1995). Briefly, splenocytes were isolated from nonmelanoma bearing
C57BL/6 mice, the GCV-treated but nonviral transduced melanoma bearing
controls and both the HSV-tk/β-gal and the HSV-tk/IL-2 transduced, melanoma
bearing mice. The splenocytes from each group were cultured for 5 d with
irradiated B16 cells. Various numbers of the stimulated splenocytes (effector
cells) where then incubated in 96 well plates with chromium 51-labeled B16
cells (target cells) and the percentage of cell lysis was determined as a function
of effector/target cell ratio.
Statistical analysis Statistical probabilities were obtained by the unpaired t
test and the Wilcoxon–Mann–Whitney U test (Fleiss, 1986). The level of
significance was set to p , 0.05.
RESULTS AND DISCUSSION
A cancer vaccination: ex vivo adenovirus-mediated immuno-
gene therapy for melanoma metastasis One potential strategy to
treat the problem of melanoma metastasis is to introduce genes that
recruit the immune system to eliminate tumors and protect against
recurrence. In the ex vivo approach, tumor cells are transduced in vitro
with cytokine genes, irradiated to avoid tumor regrowth, and returned
to the host. In previous animal models, such strategies employing
retrovirus-mediated gene delivery have protected animals against a
subsequent challenge with unmodified tumor cells that represent
metastasis. Given the fact that an ex vivo strategy stems from the lack
of efficient in vivo tumor cell transduction, e.g., due to low retroviral
titers, coupled with the problem of insertional mutagenesis from
retroviral integration, this study employed high titer, nonintegrating
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Figure 1. IL-2 secretion in vitro following B16 melanoma cell
transduction by IL-2/adv at the MOI indicated. As a control, β-gal/adv
infection was performed in parallel. Three days after onset of adv exposure,
supernatants were harvested and IL-2 secretion was determined using (A) a
mouse IL-2 ELISA and (B) a T cell proliferation bioassay. Both assays
demonstrated secretion of IL-2 in a MOI-dependent manner.
Figure 2. GM-CSF secretion determined by ELISA in triplicate dishes
following transduction of B16 melanoma cells by GM-CSF/adv in vitro.
(A) GM-CSF secretion by B16 cells into the culture supernatant 3 d after
exposure to GM-CSF/adv was MOI dependant. (B) GM-CSF secretion
following γ-irradiation (80 Gy caesium-137) 1 d after exposure of B16 target
cells to GM-CSF/adv at a MOI of 150 pfu per cell. The culture medium was
replaced immediately after γ-irradiation and analyzed for secreted GM-CSF 3
d later. Irradiation appears to lead to an elevated GM-CSF secretion.
adenoviruses to transduce B16 melanoma cells with the cytokines
IL-2 and GM-CSF in vitro, and determined their efficacy in protecting
C57BL/6 mice against experimental metastasis.
Initially, cytokine secretion levels of transduced B16 cells were
determined. For IL-2 transduction, both an ELISA (Fig 1A) and a
T cell proliferation bioassay (Fig 1B) showed that secretion levels
correlated directly with MOI, and peaked at 4–5 ng (i.e., 150–190 U)
of IL-2 per culture dish, at an MOI of 900. This gave an average IL-2
secretion rate of 15, 125, and 425 U per 106 cells per 24 h for MOI
of 100, 300, and 900 pfu IL-2/adv per cell, respectively. Currently,
there is confusion regarding whether a greater efficacy is obtained by
smaller numbers of high IL-2 secreting cells (Dranoff et al, 1993), or
by larger numbers of cells with a lower secretion rate (Zatloukal et al,
1995). As Porgador et al (1993) observed specific anti-tumor T effector
cell activation in tumor cells secreting low levels of IL-2, whereas high
IL-2 secretion levels recruited unspecific non-T cell effectors, it may
be that a biphasic curve exists for IL-2-secreting tumor vaccines
efficacy, in which efficacy is initially satisfactory but decreases at higher
secretion rates. These data led us to use adv-transduced B16 cells with
a relatively low MOI of 100 pfu of IL-2/adv per cell, but administered
in a relatively high number (4 3 106) of cells, and this proved to be
efficacious (see below).
GM-CSF secretion levels were also directly proportional to MOI,
with maximal levels observed at an MOI of 900 pfu per cell (10 ng
GM-CSF per culture dish) (Fig 2A). An MOI of 100 pfu of GM-
CSF/adv per cell gave a secretion rate of 5 ng per 106 cells per 24 h
(Fig 2A), and this secretion level was used for the ex vivo approach.
Figure 3. Protective effects of an ex vivo cancer vaccination approach
to treat experimental, distant melanoma metastasis. Two s.c. injections
(days 1 and 8) of cytokine-transduced, γ-irradiated B16 melanoma cells gave
protection against experimental metastasis mimicked by a distant site challenge
(day 15) with unmodified B16 cells. Significant reduction (p , 0.05) in
melanoma volume of the challenge tumors was achieved by transduction with
GM-CSF/adv (reduced by 88%) and IL-2/adv (reduced by 75%) in comparison
with control DL312/adv alone (100%). Additional control groups (not shown),
employing sham-vaccinated animals injected with PBS or animals injected with
γ-irradiated, uninfected B16 cells, gave identical results to those of the DL312/
adv control with regard to challenge tumor size. For TNF-α transduction,
although tumor size reduction was suggestive in this model, the data were
outside the limits set for significance.
One critical aspect of the ex vivo approach in clinical applications is
irradiation to destroy the tumorigenic potential of the tumor cells
(Pardoll, 1995). Thus, the effect of γ-irradiation on GM-CSF secretion
levels was determined. A dosage of 80 Gy of γ-irradiation, which
eliminated tumor growth, demonstrated a radiation-related enhance-
ment of GM-CSF secretion (Fig 2B). This effect was further enhanced
when B16 cells were first γ-irradiated and then exposed to adv (not
shown), a phenomenon also reported for adeno-associated virus-
mediated gene transfer (Alexander et al, 1996).
Having observed efficient adenovirus transduction and cytokine
secretion following γ-irradiation of B16 cells, we initiated an ex vivo
immuno-gene therapy approach to assess the efficacy of these cytokines
in protecting against a challenge with unmodified B16 cells. Mice
receiving vaccinations of cells secreting IL-2 or GM-CSF exhibited
significantly reduced challenge tumor growth rates (Fig 3). In compari-
son with the control groups, comprised of γ-irradiated B16 cells
transduced with DL312/adv [average tumor size 2152 mm3 (100%)],
treatment with cytokine transduced tumor cells resulted in a 75%
reduction in growth rate for IL-2 (tumor volume 530 mm3;
p 5 0.0206) and an 88% reduction with GM-CSF (tumor volume
255 mm3; p 5 0.0006). We also assessed TNF-α/adv, and as observed
previously via retroviral transduction (Dranoff et al, 1993), the effect
of TNF-α treatment was not significant (p 5 0.0653).
Whereas these data are consistent with studies using retroviral,
nonviral, and receptor-mediated delivery techniques, confirming that
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Figure 4. In vivo transduction of B16 melanomas with b-gal/adv and
inhibition of tumor growth by tk/adv/GCV treatment. (A) Time course
of adenoviral expression in vivo determined by transfer of the β-gal reporter
gene. β-gal activity was measured in homogenates from a minimum of three
tumors for each time point following direct intratumoral injection of 1 3 109
pfu of β-gal/adv. Background activity in untreated tumors (54 6 31 µU per
mm3, n 5 5) was subtracted from each enzyme activity presented. (B) Efficacy
of the HSV-tk/GCV suicide gene therapy approach alone in this B16-C57Bl/
6 model. Data presented represent transduction of B16 melanomas with tk/adv
and treatment for 6 d with 75 mg i.p. GCV per kg. Significance values
(p , 0.05) relate to a tumor volume increase in each experimental group
compared with that of the vehicle buffer/NaCl control group. A significant
result was recorded by infection with adenovirus alone, possibly due to the
immungenicity of adenovirus in this model. A similar result was observed in a
repeat experiment employing a 10 mg GCV per kg i.p. treatment regime
(not shown).
GM-CSF was the most efficacious (Zatloukal et al, 1995; Armstrong
et al, 1996), in this study, unlike the findings of Dranoff et al (1993)
where GM-CSF provided a complete protection against distant site
challenge, eventually all animals succumbed to the challenge tumors.
One potential explanation for this difference is that immunologic
clearance mechanisms, which are directed against adenoviral infection
(Wilson, 1996), may have reduced B16 cytokine expression levels
with time.
In vivo adenovirus-mediated combination gene therapy The
development of an in vivo gene therapy approach is important for easy
application in clinical settings, e.g., to avoid culture of primary tumor
cells, which is not always successful and may result in loss of tumor-
associated antigens (Nabel and Nabel, 1995). In this study the efficacy
of combined tumor treatment with cytokines and a cytotoxic HSV-
tk/GCV treatment was assessed. Initially, the optimum time point for
B16 challenge injections was determined via reporter gene delivery
and assessment of expression time course (Fig 4A). A peak average of
271 mU β-gal activity was observed at day 9, levelling off to 46 mU
at day 15. This fall off in expression may be explained by a cell division
dilution of unintegrated β-gal/adv, and/or an immune response elicited
by the immunogenicity of the expressed adenoviral genes (Wilson,
1996). Previously, adenovirus-mediated HSV-tk/GCV suicide gene
therapy was successfully evaluated in vivo employing athymic nude
mice (Bonnekoh et al, 1995) and was assessed in this immunocompetent,
B16/C57BL/6 model to determine the minimum level of GCV dose
required for maximum effect. Intratumoral injection of B16 melanomas
with 1 3 109 pfu of tk/adv and subsequent i.p. application of 75 mg
GCV per kg body weight twice daily over 6 d, resulted in a significant
55% reduction in tumor volume increase as compared with the vehicle
controls (p 5 0.008) (Fig 4B). A significant 29% reduction of the
tumor volume increase (p 5 0.014) was also observed in the HSV-tk/
adv/NaCl control group. As this tumor-suppressive effect was not
observed in the immunocompromised athymic model (Bonnekoh et al,
1995), it is probably a reflection of the immunologic clearance
mechanisms directed against adv-infected cells. In a repeat experiment,
GCV was administered at a reduced dosage of 10 mg per kg (the daily
clinical dose administered to humans), and as similar results were
obtained (data not shown), this dose was subsequently employed.
The efficacy of two experimental treatment groups was assessed.
One experiment evaluated combination gene therapy with IL-2, the
Figure 5. Induction of a systemically protective anti-tumor defence
following combination gene therapy. (A) B16 melanomas were transduced
with IL-2/adv and tk/adv (at a ratio of 1:4) or control β-gal/adv and tk/adv
(1:4 ratio) and treated with GCV (10 mg per kg i.p.) for 6 d. Primary tumors
were then excised and mice challenged with unmodified B16 cells. Two weeks
later, the average challenge tumor volume was measured. IL-2 treatment resulted
in a 56% reduction in tumor growth when directly compared with the β-gal/
tk/adv/GCV treated control group (p 5 0.041). (B) Efficacy of a double-
cytokine combination gene therapy. In this experiment, the average volume of
the challenge tumors in the animal group treated with both GM-CSF and IL-
2 was reduced by 77% compared with that of the noncytokine, β-gal/tk/adv/
GCV control group (p 5 0.037).
second evaluated the efficacy of treatment with both IL-2 and GM-
CSF. Each tumor was injected with tk/adv to provide the cytotoxic
suicide gene therapy, along with adv expressing cytokines. As observed
previously in a study of adenovirus-mediated combination gene therapy
to treat colon tumor metastases (Chen et al, 1996), no efficacy of
cytokine treatment alone was observed (data not shown). In the first
experiment, primary melanomas were injected with IL-2/tk/adv or β-
gal/tk/adv and treated with GCV. No significant difference in reduction
of growth of primary tumors was observed between the IL-2/tk/adv/
GCV treatment and the β-gal/tk/adv/GCV control (data not shown).
Following excision of the primary tumor, animals were challenged by
a s.c. injection of 5 3 104 unmodified B16 cells and a significant
reduction in challenge tumor volume was observed in the cytokine
treated group (Fig 5A). In a direct comparison with the β-gal/tk/
adv/GCV control group, the average volume of the IL-2/tk/adv/
GCV challenge tumors was 102 mm3 (p 5 0.041) vs 230 mm3 in the
controls, representing a reduced growth rate of 56%.
A similar result was obtained in the treatment of experimental colon
metastases with the IL-2/tk/adv/GCV combination therapy (Chen
et al, 1996). In this report, this effect was accompanied by the induction
of a tumor cell-specific CTL activity demonstrated in splenocyte
cultures that could be blocked completely by monoclonal anti-CD8
antibodies, but was insensitive towards anti-CD4 antibodies (Chen
et al, 1996). In this study, a 51Cr release-CTL assay was performed on
splenocytes isolated at day 21 following primary melanoma transduction
with IL-2/tk/adv/GCV or various noncytokine controls (Fig 6). Only
splenocytes isolated from the IL-2/tk/adv/GCV treatment group
demonstrated a significant increase in B16-specific CTL activity. The
relative strength of this adenoviral transduced B16 cell-mediated CTL
effect was similar to that previously reported by Dranoff et al (1993);
and supports a specific T cell response against B16 cells per se, rather
than a general anti-tumor response to transduced, cytokine producing
B16 cells.
In the second experiment, the treatment strategy comprised the
combination of GM-CSF/adv and IL-2/adv with tk/adv (Fig 5B). In
addition, the standard treatment protocol was modified by an injection
of interferon-γ (s.c., 0.8 µg per kg) 3 d before the excision of the
primary adv-treated tumor tissue. The rationale for this modification
was based upon in vitro data (not shown) that demonstrated a highly
efficient upregulation of major histocompatibility complex class I and
II epitopes on B16 cells from a 24 h incubation with interferon-γ (10
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Figure 6. Demonstration of a B16 specific cytotoxic T lymphocyte
response in animals following melanoma transduction with IL-2 in vivo.
Splenocytes were isolated from animals in the various treatment groups at 3 d
after the completion of GCV administration. Six 3 106 splenocytes were then
stimulated in vitro by cocultivation with 0.5–2 3 105 irradiated, B16 melanoma
cells for 5 d prior to the 51Cr release assay. The percentage B16 melanoma
target cell lysis was plotted versus effector/target cell ratios. Data represent mean
specific 51Cr release from triplicate cultures. Only splenocytes isolated from the
IL-2/tk/adv/GCV treatment group demonstrated a significant increase in B16
target cell lysis.
or 50 U per ml), thus potentially enhancing tumor-associated antigen
presentation. Primary adv-treated tumors were excised at day 7 after
the intratumoral virus injection, and again no significant difference in
residual tumor mass was detected comparing the GM-CSF/IL-2/tk/
adv/GCV and the β-gal/tk/adv/GCV treatment groups (data not
shown). In contrast, the GM-CSF/IL-2/tk/adv/GCV challenge tumors
exhibited a significant reduction of the average volume (75 mm3; p 5
0.037), reducing the tumor growth rate by 77% in comparison with
the control (319 mm3, 100%), and exceeding the efficacy of the IL-
2/tk/adv/treatment strategy. Although survival was prolonged with
the combination gene therapy treatment, mice eventually succumbed
to the challenge tumors, most likely due to a reduction in cytokine
expression levels as a result of an immune response against the
adenoviral vector.
In summary, this study demonstrates the potential of an adenoviral
based delivery system, via either ex vivo or in vivo gene transfer strategies,
to provide some paracrine cytokine-mediated defence against micro
and distant melanoma metastases; however, it also reveals that these
adenoviral vectors were unable to provide long-term protection. It is
anticipated that the development of a new generation of adenoviral
vectors, modified to eliminate all viral open reading frames (Kochanek
et al, 1996), will avoid immunologic clearance mechanisms directed
against adenoviral infection (Wilson, 1996) and will allow prolonged
expression of these cytokines. In addition, it should also be re-
emphasized that the effects exhibited in this model may under-represent
that which may be expected in humans given the increased sensitivity
of human melanoma cells to infection by adenoviral vectors (Bonnekoh
et al, 1996).
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